ELMINDA LTD

Their core work

ElMindA is an Israeli neurotechnology SME that develops AI-powered brain analytics software for clinical decision-making in psychiatry. Their core technology analyzes EEG signals to extract "neuromarkers" — objective, quantifiable measures of brain network activation — that can predict how a patient will respond to antidepressant treatments, including transcranial magnetic stimulation, before the treatment begins. They are essentially building the data infrastructure for personalized medicine in depression: replacing trial-and-error prescribing with predictive analytics grounded in brain physiology. Their H2020 work advanced this from feasibility concept to a Big Data platform ready for clinical deployment.

What they specialise in

How they've shifted over time

ElMindA's H2020 trajectory is a single, focused two-step development: a 2018 SME Phase 1 feasibility study (EUR 50K) that validated the market and technical approach, followed immediately by a 2019 SME Phase 2 full innovation project (EUR 1.96M) to build the actual platform. There is no keyword data from Phase 1, which is typical — Phase 1 is a business case, not deep R&D. All the technical substance (EEG analysis, AI, neuromarkers, depression, TMS) belongs to Phase 2, reflecting the shift from concept validation to product development. The trajectory shows a company that identified a narrow clinical problem early and has stayed locked onto it rather than diversifying.

ElMindA is deepening into clinical AI for neurology and psychiatry, and any future collaboration they seek will likely be in digital health, clinical trial design, or precision psychiatry — not adjacent tech sectors.

How they like to work

ElMindA has acted exclusively as coordinator across both H2020 projects, and the SME instrument they used (Phase 1 and Phase 2) is specifically designed for single-company innovation — meaning no consortium partners appear in the data. This does not mean they cannot collaborate, but their H2020 record shows an independent, product-focused operating style rather than a consortium-building one. Scientists or businesses approaching them should expect a company that knows what it wants and leads its own agenda rather than joining someone else's project as a supporting partner.

ElMindA's H2020 participation involved no formal consortium partners and no cross-country collaboration, consistent with the solo-applicant structure of the SME instrument. Their network in the broader neurotechnology and clinical research space is not visible from this dataset.

What sets them apart

ElMindA occupies a specific and underserved niche: they are not a general AI health company, but a specialist in brain-signal biomarkers for psychiatric treatment selection — a problem that has resisted solution for decades. Their combination of EEG signal processing, brain network modeling, and machine learning applied specifically to depression and TMS response is difficult to replicate without deep neuroscience IP. For a consortium needing clinical AI credibility in neuropsychiatry, they bring both the technical platform and the regulatory-pathway experience that comes from advancing through two consecutive EU funding phases.

Highlights from their portfolio

• PREDICT
  The EUR 1.96M Phase 2 project is the company's flagship — a full-scale Big Data EEG platform targeting personalized medicine in depression, one of the most commercially and clinically significant unmet needs in psychiatry.
• PREDICT
  The EUR 50K Phase 1 feasibility study demonstrates a disciplined commercialization path through the SME instrument, with the company successfully converting a validated concept into a multi-million-euro development award within one year.